Form 8-K - Current report:
SEC Accession No. 0000950170-24-122814
Filing Date
2024-11-07
Accepted
2024-11-07 08:00:07
Documents
13
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vera-20241107.htm   iXBRL 8-K 47944
2 EX-99.1 vera-ex99_1.htm EX-99.1 122500
3 GRAPHIC img47757703_0.jpg GRAPHIC 8863
  Complete submission text file 0000950170-24-122814.txt   312399

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vera-20241107.xsd EX-101.SCH 26983
15 EXTRACTED XBRL INSTANCE DOCUMENT vera-20241107_htm.xml XML 4901
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 1200 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 1200 BRISBANE CA 94005 650-770-0077
Vera Therapeutics, Inc. (Filer) CIK: 0001831828 (see all company filings)

EIN.: 812744449 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40407 | Film No.: 241433260
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)